Abstract
Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 410-414 |
| Number of pages | 5 |
| Journal | Current Oncology Reports |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2005 |
Fingerprint
Cite this
New paradigms for therapy for osteosarcoma. / Nagarajan, Rajaram; Clohisy, Denis; Weigel, Brenda.
In: Current Oncology Reports, Vol. 7, No. 6, 11.2005, p. 410-414.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - New paradigms for therapy for osteosarcoma
AU - Nagarajan, Rajaram
AU - Clohisy, Denis
AU - Weigel, Brenda
PY - 2005/11
Y1 - 2005/11
N2 - Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.
AB - Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.
UR - http://www.scopus.com/inward/record.url?scp=28044464033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28044464033&partnerID=8YFLogxK
U2 - 10.1007/s11912-005-0005-1
DO - 10.1007/s11912-005-0005-1
M3 - Review article
C2 - 16221377
AN - SCOPUS:28044464033
VL - 7
SP - 410
EP - 414
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 6
ER -